Akoya Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2016 - 2020
Net Income	-	33.57	16.86	-12.66	36.23	-2.36	Upgrade
Depreciation & Amortization	-	0.1	0.05	0.07	0.11	0.49	Upgrade
Loss (Gain) From Sale of Assets	-	-0.02	-0.66	-0.21	-4.56	-0.65	Upgrade
Loss (Gain) From Sale of Investments	-	-41.42	-13.96	23.51	-38.77	9.89	Upgrade
Other Operating Activities	-	-0.21	-0.13	-0.47	0.07	0.88	Upgrade
Change in Accounts Payable	-	-0.18	-0.24	-0.44	-0.85	0.85	Upgrade
Change in Income Taxes	-	0.04	1.8	0.79	-2.48	-0.12	Upgrade
Operating Cash Flow	-	3.91	7.11	3.27	-4.44	22.46	Upgrade
Operating Cash Flow Growth	-	-45.06%	117.53%	-	-	-60.24%	Upgrade
Sale of Property, Plant & Equipment	-	0.31	2.14	1.15	2.77	1.1	Upgrade
Divestitures	-	-	-	-	4.52	-	Upgrade
Investment in Securities	-	-18.56	-18.06	4.97	-69.57	39.34	Upgrade
Other Investing Activities	-	4.36	3.73	0.06	5.24	58.32	Upgrade
Investing Cash Flow	-	-12.01	-8.49	19.25	-49.23	98.06	Upgrade
Repurchase of Common Stock	-	-6.57	-9.36	-	-	-	Upgrade
Common Dividends Paid	-	-3.72	-	-5.76	-5.55	-5.35	Upgrade
Other Financing Activities	-	-	-	-	-56.81	-30.94	Upgrade
Financing Cash Flow	-	-10.29	-9.36	-5.76	-62.36	-36.29	Upgrade
Net Cash Flow	-	-18.39	-10.74	16.76	-116.04	84.23	Upgrade
Cash Interest Paid	-	-	-	-	0.04	0.4	Upgrade
Cash Income Tax Paid	-	0.87	-0.28	0.2	7.27	2.72	Upgrade
Levered Free Cash Flow	-	35.2	22.54	3.91	2.26	-	Upgrade
Unlevered Free Cash Flow	-	35.2	22.54	3.91	2.26	-	Upgrade
Change in Working Capital	-	11.97	5.11	-6.76	2.77	0.2	Upgrade

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.